ArticleAnnals of surgical oncology2026
Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe COVID-19 pandemic restricted operating room availability, prompting the Pandemic Breast Cancer Consortium to issue guidelines on deferring non-urgent surgical procedures. This led to an increased use of neoadjuvant endocrine therapy (NET) for estrogen-receptor positive (ER+) breast cancers. Irrespective of the pandemic, the ACOSOG Z1031 trial demonstrated that NET was effective at downstaging 51% of patients initially ineligible for breast conserving surgery (BCS). Despite this, NET utilization remains low. This study investigates NET use and related outcomes before, during, and after the pandemic.
methodsPatients aged ≥ 18 with clinical T1-T4c, N0-3, ER+/HER2- breast cancers were selected from the National Cancer Database and stratified into two groups: NET versus surgery first. The study analyzed trends from 2019 (pre-pandemic) to 2021 (tail-end-pandemic). Logistic regression identified factors associated with NET utilization.
resultsResults showed that 10,935 (3.9%) patients received NET and 272,546 (96.1%) underwent surgery first. NET use peaked in 2020 at 6.4% (vs. 2019 2.3% and 2021 3.2%, P = 0.001). Median time from diagnosis to treatment was significantly shorter in the NET group (1.02 vs. 1.35 months, P = 0.001). Patients with clinical T3-4 disease who received NET versus surgery first had similar rates of BCS and were less likely to receive chemotherapy.
conclusionThe use of NET nearly tripled during the COVID-19 pandemic and was associated with decreased time to treatment and less use of adjuvant chemotherapy. NET could be considered for patients requiring a delay to surgery or for those with higher T-category who desire BCS or are unable to tolerate chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.